Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenon Medical, Inc. (NASDAQ: TNON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tenon is a medical device company focused on sacroiliac (SI) joint and sacro-pelvic fusion systems, including the Catamaran and SImmetry platforms. Its filings give investors detailed information on capital raising transactions, acquisitions, equity compensation, governance decisions and financial reporting related to this sacro-pelvic fusion business.
Recent Form 8‑K filings describe material events such as the November 10, 2025 securities purchase agreements for an at‑the‑market PIPE financing, in which Tenon agreed to issue common stock and common stock purchase warrants, generating approximately $2.85 million in gross proceeds for working capital and general corporate purposes. Another 8‑K filed on August 6, 2025 outlines the asset purchase agreements for the SiVantage (SImmetry business) and SIMPL Medical portfolios, including cash, equity, royalty and earnout components, along with related employment agreements for key executives joining Tenon.
Filings also cover equity and governance matters. An 8‑K dated October 16, 2025 reports the issuance of restricted stock units to Tenon’s directors and officers under the 2022 Equity Incentive Plan, with specified vesting schedules. An 8‑K filed September 23, 2025 details the results of the 2025 Annual Meeting of Stockholders, including election of directors, approval of warrant exercisability, amendments to the equity incentive plan and ratification of the independent auditor. An 8‑K/A filed October 17, 2025 provides financial statements of SiVantage and unaudited pro forma condensed combined financial information reflecting the acquisition.
Through Tenon’s periodic reports and accompanying exhibits, investors can review condensed balance sheets, statements of operations and comprehensive loss, and pro forma financials that show how acquisitions affect the company’s financial position. Stock Titan enhances this information with AI-powered summaries that explain key terms in plain language, highlight important elements of PIPE financings, asset purchase agreements and equity awards, and help users quickly identify items such as warrant terms, earnout structures and royalty obligations. The filings page also surfaces insider-related equity grants reported in 8‑Ks, giving a clearer view of how management and directors are compensated through stock and restricted stock units.
By combining real-time EDGAR updates with AI-generated insights, the Tenon Medical filings section helps users understand how capital structure changes, acquisitions of sacro-pelvic technologies and governance decisions relate to the company’s strategy in SI joint fusion and sacro-pelvic fixation.
Tenon Medical (TNON) reported an insider equity grant. Director and Chief Technology Officer Richard Ginn received 253,153 restricted stock units (RSUs) on 10/13/2025. Each RSU represents the right to receive one share of common stock.
The RSUs vest in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the derivative security price as $0 and indicates direct ownership following the transaction.
Tenon Medical (TNON) reported an insider equity grant on Form 4. Chief Financial Officer and Director Kevin Williamson was awarded 117,974 restricted stock units (RSUs) on 10/13/2025.
Each RSU represents the right to receive one share of common stock. The grant vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the reported transaction, 117,974 derivative securities were beneficially owned, held directly.
Tenon Medical (TNON)281,872 restricted stock units on October 13, 2025. Each RSU represents the right to receive one share of Tenon common stock. The filing states a derivative security price of $0.
The award vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. The ownership reported for these derivative securities is Direct.
Tenon Medical (TNON) reported a director equity grant. On 10/13/2025, a director received 21,464 restricted stock units (RSUs) at a price of $0, as disclosed in a Form 4 filing.
Each RSU represents the right to receive one share of common stock. The vesting schedule splits evenly: 50% of the RSUs vest and convert into common stock on January 1, 2026, and the remaining 50% vest and convert on July 31, 2026. Following the grant, the reporting person held 21,464 derivative securities directly.
Tenon Medical (TNON) reported an insider equity award. A director received 20,293 restricted stock units (RSUs) on 10/13/2025, recorded at $0 as typical for RSU grants. Each RSU represents the right to receive one share of common stock.
The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026, after which the vested RSUs automatically convert into common shares on a one-for-one basis. Following the reported transaction, the director held 20,293 derivative securities directly.
Tenon Medical (TNON)Richard Ferrari received 128,957 restricted stock units (RSUs) on October 13, 2025. Each RSU represents a right to receive one share of common stock. The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the transaction at $0 per unit and shows direct ownership of the RSUs following the grant.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.
Nathaniel A. Grawey, Chief Commercial Officer of Tenon Medical (TNON), reported beneficial ownership on a Form 3. He directly holds 138,114 shares of common stock, which are stated to be subject to a vesting schedule and non-transferable, and has an indirect interest in 175,383 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Grawey holds 24.69% of that company.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
